IRVINE, Calif., June 12, 2007 (PRIME NEWSWIRE) -- An Executive Informational Overview(r) (EIO(r)) on Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) has been released by Crystal Research Associates, LLC. The full 52-page report is available at www.crystalra.com
Millennium Biotechnologies Group, Inc. ("Millennium" or "the Company") engages in the research, development, and marketing of specialized nutritional supplements as an adjunct to medical treatments for select medical conditions, as well as for individuals seeking improved recovery and advanced performance. The Company's marketed products are targeted toward immuno-compromised individuals undergoing medical treatment for diseases, such as cancer, as well as individuals living with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and wound healing and post-surgical healing, among other conditions.
Millennium's three proprietary, marketed products, which form the Company's Resurgex(r) Continuum of Care, include Resurgex Select(r), Resurgex(r), and Resurgex Plus(r). Resurgex Select(r) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(r) and Resurgex Plus(r) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also developing a Resurgex(r) Fusion sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.
A detailed report regarding Millennium Biotechnologies, Inc. is available free to the investing public at the following link:
http://stockupticks.com/profiles/11-28-06.html
The report "Better Mousetrap Files" has been made available free of charge at www.SmallCapSentinel.com and will address preeminent and emerging companies such as N B T Y Inc. (NYSE:NTY), Schiff Nutrition International, Inc. (NYSE:WNI), Nutrition 21 Inc (Nasdaq:NXXI), and Millennium Biotechnologies.
Individuals may also register to receive future reports on emergent public companies at:
http://stockupticks.com/register.html
To be featured in SmallCap Sentinel or StockUpTicks.com please use the contact information below or email sts@marketpathways.com
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been paid $24,000 by Millennium Biotechnologies for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664